[1] |
FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua.
Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
|
[2] |
WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai.
Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
|
[3] |
WU Xianchuang, LIU Yuxin, NIU Yuji, HE Jinjin, QIAO Hui, ZHANG Leilei.
Mechanism of DCLK1 transcriptional regulation in HCC
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1241-1246.
|
[4] |
DING Jiamin, WANG Youdi, ZHAO Xiali, JIANG Genfeng, CHEN Siwen, HONG Chengcheng, LI Shuqin, HU Weihua.
Study on the treatment of thin endometrium with growth hormone and vitamin E
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 857-862.
|
[5] |
SUI Yuxia, ZHUANG Jie, ZHUANG Min, HUANG Gui.
Delicaflavone inhibits the invasion and migration of gefitinib-resistant lung cancer PC-9/GR cells by regulating epithelial-mesenchymal transition via PI3K/Akt/mTOR pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 614-621.
|
[6] |
WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong.
Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
|
[7] |
LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui.
circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
|
[8] |
LEI Jing, HE Ping, CAI Wenlin, ZHANG Yongzhe, ZHANG Beiru, LIU Dajun.
Cordyceps sinensis extracts attenuates HBx-induced mesangial cell proliferation and extracellular matrix synthesis by suppression of the PI3K/Akt pathways
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1247-1254.
|
[9] |
YE Kaili, ZHENG Wen, YE Qifa, YANG Lan .
Mechanism of CDK1 participates in the development of hepatocellular carcinoma and its inhibitor application value
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1086-1094.
|
[10] |
YU Saihong, ZHENG Xiaoliang, PU Yiyi, YAN Dongmei, WANG Xiaoju, YU Jie.
Reversal of 5-fluorouracil resistance in hepatocellular carcinoma cells by inhibiting ribonucleotide reductase M2
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 729-737.
|
[11] |
SONG Ruzheng, PENG Ying, WANG Guangji, SUN Jianguo.
Commonly used quantitative proteomics research techniques and their application in the study of pathogenesis of liver-derived diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 570-578.
|
[12] |
JIANG Yuhua, ZHI Hui, LU Linming, TIAN Dahao, WANG Xiaoqing, GE Yu, XIE Shangfu, WANG Qi.
AHVAC-I reverses tumor growth of cancer-associated fibroblasats in gastric cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 389-394.
|
[13] |
CHEN Linjun, CHEN Wenbin.
Jolkinolide B inhibits the proliferation and metastasis of colon cancer cells via blocking PI3K/Akt/NF-κB pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 250-257.
|
[14] |
PENG Fusheng, HUANG Xiaohui, LI Peng, TANG Jian'er.
miR-34a inhibits proliferation of prostate cancer LNCaP cells by regulating androgen receptor gene
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 10-17.
|
[15] |
WANG Xianghai, XING Min, LYU Tangfeng, LIU Hongbing, SONG Yong.
Effects of knocking down long intergenic non-coding RNA 00467 on the prognosis of patients with lung adenocarcinoma and its mechanism
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 841-849.
|